Selective progesterone receptor modulators 1: use during pregnancy
- 8 September 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (14) , 2459-2472
Abstract
A large number of synthetic compounds known as selective progesterone receptor modulators can bind to progesterone receptors: the ligands exhibit a spectrum of activities ranging from pure antagonism to a mixture of agonism and antagonism. Only a dozen or so selective progesterone receptor modulators have been tested to any significant extent: among them are mifepristone (RU 486), asoprisnil (J867), onapristone (ZK 98 299), ulipristal (CDB 2914), Proellex() (CDB 4124), ORG 33628 and ORG 31710. Their clinical applications during pregnancy are discussed. A careful evaluation of existing major review papers and recently published articles was carried out focusing on mifepristone, the most widely studied selective progesterone receptor modulator, which was first used for the voluntary interruption of an early gestation. Other selective progesterone receptor modulators, especially those with partial agonist action, have shown little activity during pregnancy in animal models. Besides early and late voluntary interruption of gestation, selective progesterone receptor modulators have been tested in a variety of obstetrical situations: to obtain a ripening of the cervix, for the medical management of early embryonic loss and foetal death, for the induction of labour at term and for the medical treatment of extra-uterine pregnancies. The only applications that seem worthy of large-scale utilisation during pregnancy are voluntary interruption of early and late gestation, medical management of early delayed miscarriage and late foetal demiseKeywords
This publication has 77 references indexed in Scilit:
- Uterine Activity after Oral Mifepristone Administration in Human Pregnancies beyond 41 Weeks’ GestationGynecologic and Obstetric Investigation, 2007
- Efficacy of a single misoprostol regimen in the first and second trimester termination of pregnancyJournal of Obstetrics and Gynaecology, 2007
- ACOG Committee Opinion #67: Medical Management of AbortionObstetrics & Gynecology, 2005
- Expectant, Medical, or Surgical Management of First-Trimester Miscarriage: A Meta-AnalysisObstetrics & Gynecology, 2005
- WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: EfficacyBJOG: An International Journal of Obstetrics & Gynaecology, 2003
- Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: A randomized, controlled studyAmerican Journal of Obstetrics and Gynecology, 2000
- New progestins and potential actionsJournal of the Society for Gynecologic Investigation, 2000
- Induction of labour with intravaginal misoprostol versus dinoprostone in intrauterine death: A retrospective studyJournal of Obstetrics and Gynaecology, 1996
- Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation.BMJ, 1993
- Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortionBJOG: An International Journal of Obstetrics & Gynaecology, 1990